Full-Time

Clinical Advisor - Restorative and Conservative Dentistry

Clinical Support, Dental Solutions

Posted on 8/27/2025

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

No salary listed

Milan, Metropolitan City of Milan, Italy

Remote

Remote in the north of Italy; may include up to 50% travel.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Salesforce
Data Analysis
Excel/Numbers/Sheets
Requirements
  • University education (Bachelor or Master degree) is requested
  • Dental training (University or Dental Technician) background is highly desired
  • 4 years’ experience in sales / clinical roles
  • Excellent knowledge of MS Office (Excel in particular) and Salesforce.com
  • Digital savvy to be able to work with dental digital systems
  • Fluency in English
  • Strong interpersonal, communication, presentation and listening skills
  • Sales driven, perseverance and results oriented
  • Planning and prioritization capabilities
  • Ability to build and maintain good relationship with Key Opinion Leaders
  • Customer-focus and proactive approach
  • Ability to work and deliver results under pressure
  • Capability to work with high ability to self-motivate
  • Ability to work well within a team
  • Ethical approach
Responsibilities
  • Training clinicians about Solventum products for evaluations or conversions
  • Supporting product evaluations/trials/demos with follow-up calls, troubleshooting, data analysis
  • Making joint calls with Sales Representatives and providing clinical and technical information that supports/enhances sales presentation
  • Interacting with Key Opinion Leaders (Health Care Professionals) and developing educational programs in direct collaboration with the EMEA Scientific Affairs team
  • Interacting with Dental Universities (according to ethics and compliance standards) to support product knowledge
  • Providing continuing education on products and related topics that support Solventum business objectives
  • Attending sales and/or marketing meetings and conference calls
  • Participating and supporting in customer events (congress, workshop, etc.)
  • Providing consultation to Solventum products and related applications/issues
  • Utilizing Evidence-Based approach (Scientific Studies, Health Economics, etc.)
  • Supporting Bid Office team assessing the best documentation for tenders when requested
  • Proactive cooperation with marketing team
  • Daily use of CRM including reporting of activities

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • Advanced wound care and Acera Surgical deepen Solventum’s synthetic tissue position.
  • Eagan Innovation Hub accelerates R&D in wound care, sterilization, and digital health.
  • Purification sale and 2026 buyback improve capital focus and shareholder returns.

What critics are saying

  • AI-native documentation vendors threaten the Health Information Systems revenue base.
  • ERP rollout disruptions are already distorting orders across infection prevention, surgical, and dental.
  • Dependence on volume growth leaves Solventum exposed to hospital and dental demand slowdowns.

What makes Solventum unique

  • Spin-off from 3M in April 2024 gave Solventum a focused healthcare portfolio.
  • Bryan Hanson leads four segments: MedSurg, Dental, Health Information Systems, Purification.
  • Over 7,300 patents support decades of healthcare materials and workflow innovation.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Solventum who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

0%
Simply Wall St
Apr 5th, 2026
Solventum opens $200M Innovation Hub as CAO prepares to retire

Solventum Corporation has opened a $200 million Innovation Hub in Eagan, Minnesota, housing over 1,800 employees and supported by approximately $13 million in state business development funding. The facility focuses on research and development in healthcare innovation, particularly advanced wound care, sterilisation and digital health. The opening coincides with Chief Accounting Officer Mary Wilcox announcing her retirement, effective once a successor is appointed. Wilcox informed the company of her intention on 20 March 2026. The Innovation Hub supports Solventum's emphasis on new product development following its separation from 3M. However, analysts note that near-term execution risks around ERP implementation and supply chain transition remain key factors for investors to monitor.

Yahoo Finance
Mar 1st, 2026
Solventum sells Purification unit, buys Acera Surgical, launches $1B buyback in first year post-3M spin

Solventum reported fourth-quarter sales of $2.0 billion, with organic growth of 3.5% year-over-year, though reported revenue declined 3.7% due to its Purification & Filtration divestiture and the Acera acquisition. Non-GAAP earnings per share reached $1.57, whilst adjusted operating margin was 19.9%. Gross margin fell 230 basis points to 53.5%, with roughly 150 basis points attributed to one-time separation costs from 3M. For 2026, the company guided organic sales growth of 2%–3%, operating margin of 21%–21.5%, and EPS of $6.40–$6.60. Management expects free cash flow around $200 million, or roughly $1 billion excluding separation and divestiture costs. The company closed its acquisition of Acera Surgical to enter the synthetic tissue market and launched a $1 billion share buyback programme. Solventum aims to exit approximately 90% of transitional service agreements with 3M by year-end 2026.

Yahoo Finance
Feb 26th, 2026
Solventum beats quarterly estimates as surgical product demand drives $2B revenue

Solventum, a Minnesota-based medical device maker, beat Wall Street estimates for the fourth quarter, driven by strong demand for wound care and sterilisation products. Revenue reached $2 billion, surpassing analysts' expectations of $1.96 billion, whilst adjusted earnings per share came in at $1.57 versus estimates of $1.50. The company's MedSurg business, which accounts for over half of total revenue, saw sales rise 5.2% year-on-year to $1.24 billion. Solventum forecast 2026 adjusted profit of $6.40 to $6.60 per share, above Wall Street expectations of $6.34. The company is acquiring Acera Surgical for up to $850 million to expand its wound care portfolio and has launched a four-year programme expected to deliver $500 million in annual savings.

Yahoo Finance
Feb 26th, 2026
Solventum Q4 earnings beat expectations with $2B revenue, projects $6.40-$6.60 per share for 2025

Solventum reported fourth-quarter net income of $63 million, or $1.57 per share on an adjusted basis, exceeding Wall Street expectations of $1.50 per share. The Maplewood, Minnesota-based healthcare company posted revenue of $2 billion, surpassing analyst forecasts of $1.97 billion. For the full year, Solventum reported profit of $1.56 billion, or $8.88 per share, with revenue of $8.32 billion. The company expects full-year earnings between $6.40 and $6.60 per share.

PR Newswire
Feb 26th, 2026
Solventum reports Q4 2025 results with 3.5% organic sales growth, sets 2026 guidance

Solventum reported fourth quarter 2025 results with sales of $2 billion, down 3.7% on a reported basis but up 3.5% organically. GAAP diluted earnings per share were $0.36, whilst adjusted diluted earnings per share reached $1.57. Operating cash flow totalled $96 million, with free cash flow of $33 million. The healthcare company's organic sales growth was driven by its Infection Prevention and Surgical Solutions business within MedSurg and Dental Solutions. Full-year 2025 results exceeded expectations for both sales and earnings per share. For 2026, Solventum projects organic sales growth of 2.0% to 3.0%, adjusted earnings per share of $6.40 to $6.60, and free cash flow of approximately $200 million. The company, which spun off from 3M, continues its transformation journey.

INACTIVE